Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Language
Publication year range
1.
Journal of Forensic Medicine ; (6): 365-368, 2020.
Article in English | WPRIM (Western Pacific) | ID: wpr-985127

ABSTRACT

Post traumatic epilepsy (PTE) is a serious complication of traumatic brain injury and a difficult problem in forensic justice practice. In recent years, many biomarkers have been applied to the diagnosis, treatment and prognosis of injuries and diseases. There have been many studies on the biomarkers of PTE in the field of epilepsy. This paper reviews the progress in research on biomarkers of PTE in recent years in order to provide reference for the forensic identification of PTE.


Subject(s)
Humans , Biomarkers/analysis , Brain Injuries, Traumatic/diagnosis , Epilepsy/etiology , Epilepsy, Post-Traumatic/etiology
2.
Vaccine ; 23(14): 1649-56, 2005 Feb 25.
Article in English | MEDLINE | ID: mdl-15705468

ABSTRACT

Several reports have indicated that combinatorial regimens with DNA and protein vaccines can elicit both strong immune responses, to circumvent the limits of each vaccine. Surprisingly little was known on HBV vaccine. Here, we investigated the immunization effects of several regimens in BALB/c mice. The level of total antibody and isotypes of IgG were determined by ELISA. Cellular immune responses were assayed by measuring the production of cytokines and CTL activity after re-stimulation for 7 days in vitro with tumor cells CT26/S stably expressing HBsAg. The efficacy of immunoprotection against the challenge of transplanted CT26/S was also examined. The regimen involving twice priming pVAX(S) encoding HBsAg and once recombinant HBsAg protein (rHBsAg) boosting, induced strong and homogenous antibody responses. This regimen induced significant stronger responses of interleukin-12 and gamma interferon (IFN-gamma) in splenocytes, and elicited stronger CD8+ CTL responses and greater immunopretectional efficacy than those elicited by immunization with rHBsAg or pVAX(S) alone. Our regimen may thus provide a strategy for developing an improved immunization against HBV and many other pathogens.


Subject(s)
Adjuvants, Immunologic/pharmacology , DNA, Viral/immunology , Hepatitis B Surface Antigens/immunology , Hepatitis B Vaccines/immunology , Hepatitis B/immunology , Viral Proteins/immunology , Adjuvants, Immunologic/genetics , Adjuvants, Immunologic/therapeutic use , Animals , Antibody Formation/genetics , Antibody Formation/immunology , COS Cells , Chlorocebus aethiops , Hepatitis B/prevention & control , Hepatitis B Surface Antigens/biosynthesis , Hepatitis B Surface Antigens/genetics , Hepatitis B Vaccines/pharmacology , Hepatitis B Vaccines/therapeutic use , Humans , Immunity, Cellular/genetics , Immunity, Cellular/immunology , Mice , Mice, Inbred BALB C , Transfection , Vaccines, Combined/immunology , Vaccines, Combined/pharmacology , Vaccines, Combined/therapeutic use , Viral Proteins/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...